The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 11-12, 2008, Pages 1278-1286

  Irvine, E J ^a   Yeh, C H ^b   Ramsey, D ^b   Stirling, A L ^c   Higgins, P D R ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c Medical Education Strategies LLC   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESALAMINE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 55349130988     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03854.x     Document Type: Article

References (17)

1. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002 16 : 1603 9.
2. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992 14 : 15 9.
3. Sainsbury A, Heatley RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005 21 : 499 508.
4. Irvine EJ. Quality of life in inflammatory bowel disease: biases and other factors affecting scores. Scand J Gastroenterol 1995 208 : 136 40.
5. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008 14 : 554 65.
6. Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut 2004 53 (Suppl. 4 35 9.
7. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000 95 : 999 1007.
8. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994 106 : 287 96.
9. Hlavaty T, Persoons P, Vermeire S, et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis 2006 12 : 199 204.
10. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005 54 : 782 8.
11. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007 102 : 794 802.
12. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005 100 : 2478 85.
13. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007 21 : 827 34.
14. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 96 : 804 10.
15. Han SW, McColl E, Steen N, Barton JR, Welfare MR. The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England. Scand J Gastroenterol 1998 33 : 961 6.
16. Hanauer SB, Sandborn WJ, Kornbluth A, Hardi R, Regalli G, Yeh C. Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) versus 2.4 g/day (400mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomized, double-blind, controlled trials. Gastroenterology 2005 128 : A74 5. Abstract 492.
17. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994 8 : 27 34.